Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 6-7, 2003, Pages 383-388

  Ormaasen, Vidar ^a   Bruun, Johan N ^a   Sandvik, Leiv ^a   Holberg Petersen, Mona ^a   Gaarder, Per Ivar ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PROGNOSIS; RISK FACTOR; VIRUS INHIBITION; VIRUS LOAD;

EID: 0041920963     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310009716     Document Type: Article

References (21)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the Euro-SIDA study. Lancet 2000; 356: 291-6.
3. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Arch Intern Med 2000; 160: 1123-32.
4. Lucas GM, Chaisson RF, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-7.
5. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the 31/2 years after initiation of potent antiretroviral therapy. J AIDS 2001; 27: 1668-75.
6. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16: 359-67.
7. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 1873-80.
8. Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000; 14: 1955-60.
9. DeHovitz JA, Kovacs A, Feldman JG, Anastos K, Young M, Cohen M, et al. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: a report from the women's interagency HIV study. J Infect Dis 2000; 182: 1527-30.
10. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the multicenter AIDS cohort study. AIDS 2001; 15: 735-46.
11. + cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185: 471-80.
12. Ormaasen V, Bruun JN, Sandvik L, Holberg-Petersen M, Gaarder PI. A search for optimal criteria in initiating antiretroviral therapy in chronic human immunodeficiency virus infection focusing on CD4 count and HIV RNA. Scand J Infect Dis 2002; 34: 910-7.
13. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17): 1-19.
14. Huang W, DeGruttola V, Fischl M, Hammer S, Richman D, Havlir D, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis 2001; 183: 1455-65.
15. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177: 40-7.
16. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358: 1760-5.
17. Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. Ann Intern Med 2001; 135: 954-64.
18. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-8.
19. Kitchen CM, Kitchen SG, Dubin JA, Gottlieb MS. Initial virological and immune response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis 2001; 33: 466-72.
20. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimetre. N Engl J Med 1996; 335: 1091-8.
21. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996; 174: 704-12.